Navigation Links
Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum

IRVINE, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced today that it will present an overview of the Company on Wednesday, October 10, 2007, at 4:45 p.m. Pacific, at the BIO Investor Forum, being held at the Palace Hotel in San Francisco, California. Spectrum's presentation will be held in the Sea Cliff room.

The live webcast of Spectrum's presentation will be available at Replays will be available for 30 days.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at

Forward-looking statement -- This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.


Russell Skibsted Susan Neath

SVP & Chief Business Officer Porter Novelli Life Sciences


Paul Arndt

Manager, Investor Relations


SOURCE Spectrum Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
3. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
4. Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria
5. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
6. Younger Siblings of Children With Autism Spectrum Disorders Score Low
7. Bipolar Spectrum Disorder may Be Under-recognized for Spectrum Disorder: Study
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. FDA approves Watson Pharmaceuticals Oxytrol patch
10. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating ... quality and cost of health care services available to its members to help ...
(Date:11/24/2015)... ... ... Rodney E. Willey , has answered a new calling – to relieve snoring and sleep ... snoring and sleep apnea through oral appliance therapy. He is one of ... US, one of four in the Illinois area. , Dr. Willey’s location is ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health ... have announced their endorsement of the Medical Fitness Network (MFN), a national ... to have the MFN as one of our endorsed organizations,” said ASH Fitness ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 Sectra ... has entered into a multi-year agreement to deploy ... This investment will provide the Breast Center a future-proof ... Sectra (STO: SECT B) announces that Breast Center ... to deploy Breast Imaging PACS in its two freestanding ...
(Date:11/24/2015)... Mass. , Nov. 24, 2015   HeartWare ... innovator of less-invasive, miniaturized circulatory support technologies that are ... that President and Chief Executive Officer Doug Godshall ... 27 th Annual Healthcare Conference on December 1, ... held December 1-2 in New York ...
(Date:11/24/2015)... and BERN, Switzerland , ... the ARTORG Center for Biomedical Engineering Research of the ... the Division of Endocrinology, Diabetes and Clinical Nutrition of ... the start of an exclusive collaboration to develop a ... algorithm for the personalised delivery of insulin for diabetic ...
Breaking Medicine Technology: